GeneDx Holdings Corp. (WGS)

Market Cap	2.00B
Revenue (ttm)	330.14M
Net Income (ttm)	-38.58M
Shares Out	28.53M
EPS (ttm)	-1.41
PE Ratio	n/a
Forward PE	56.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	560,222
Open	70.00
Previous Close	69.99
Day's Range	68.35 - 71.01
52-Week Range	19.54 - 117.75
Beta	2.04
Analysts	Strong Buy
Price Target	81.33 (+16.15%)
Earnings Date	Apr 30, 2025

About WGS

GeneDx Holdings Corp., a genomics company, provides genetic testing services. It primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. The company also develops an AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. The company is headquartered in Stamford, Connecticut.

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Employees: 1,000
• Stock Exchange: NASDAQ
• Ticker Symbol: WGS
• Website: https://www.genedx.com

Financial Performance

In 2024, GeneDx Holdings's revenue was $305.45 million, an increase of 50.79% compared to the previous year's $202.57 million. Losses were -$52.29 million, -70.25% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for WGS stock is "Strong Buy." The 12-month stock price forecast is $81.33, which is an increase of 16.15% from the latest price.

Price Target

$81.33

(16.15% upside)

Analyst Consensus: Strong Buy